Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.46 |
| ▸ | NPC1 | O15118 | 11/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4722546 | 0.84 | RAB9A (0.42) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL18317226 | 0.82 | RAB9A (0.40) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL18317174 | 0.80 | HPRT1 (0.42) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL18317225 | 0.77 | RAB9A (0.42) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL10742470 | 0.77 | KDM4E (0.39) | CYP1A2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL30883993 | 0.77 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL239122 | 0.77 | CYP2A6 (0.37) | CYP3A4CYP1A2ALDH1A1HSD17B10HPGD | |
| SCHEMBL30883995 | 0.77 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL29374931 | 0.75 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL170196 | 0.75 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | disclosed |
| US-9812652-B2 | Cyclic azine compound having adamantyl group, production method, and organic electroluminescent device containing it as constituent component | TOSOH CORPORATION (JP) | 2017-11-07 | — | — | US | disclosed |
| US-20160372678-A1 | CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2015-06-04 | — | — | US | disclosed |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION | 2015-05-07 | — | — | US | disclosed |
| US-8946262-B2 | Methods of preventing and treating gastrointestinal dysfunction | ADOLOR CORPORATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-10-09 | — | — | US | disclosed |
| US-20140057947-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| US-8598207-B2 | Compositions containing opioid antagonists | ADOLOR CORPORATION (US) | 2013-12-03 | — | — | US | disclosed |
| US-8404693-B2 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2006079916-A1 | THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2005117873-A2 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272776-A1 | Such as alvimopan and active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits; lyophilization; vacuum drying; storage stability | ADOLOR CORPORATION (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050148630-A1 | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | disclosed |
| WO-2005055953-A2 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056011-A1 | METHODS OF PREVENTING AND TREATING NON-OPIOID INDUCED GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | MERCK SHARP & DOHME LLC | 2005-06-09 | — | — | US | disclosed |
| WO-2004082623-A2 | SUBSTITUTED PIPERIDINE COMPOUNDS | ADOLOR CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186135-A1 | Substituted piperidine compounds | CUBIST PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-0919544-A1 | Compounds useful for treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057947-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | RAB9A 3478/4885NPC1 2981/4885CYP3A4 146/4885 |
| US-20040186135-A1 | Substituted piperidine compounds | OPRK1, OPRD1, OPRM1 | RAB9A 1123/4885NPC1 992/4885CYP3A4 374/4885 |
| US-20160372678-A1 | CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT | CHRM1, AFF1, AZI2 | RAB9A 1464/4885NPC1 2628/4885CYP3A4 379/4885 |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | VIP, FABP2, SI | RAB9A 3674/4885NPC1 4447/4885CYP3A4 384/4885 |
| US-20050272776-A1 | Such as alvimopan and active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits; lyophilization; vacuum drying; storage stability | OPRK1, LPXN, OPRM1 | RAB9A 2417/4885NPC1 2643/4885CYP3A4 143/4885 |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | PNMT, VIP, PREP | RAB9A 2038/4885NPC1 4148/4885CYP3A4 215/4885 |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | RAB9A 3478/4885NPC1 2981/4885CYP3A4 146/4885 |
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRD1 | RAB9A 2082/4885NPC1 1473/4885CYP3A4 55/4885 |
| US-20050148630-A1 | Methods of preventing and treating non-opioid induced gastrointestinal dysfunction | SLC10A2, OPRK1, FABP2 | RAB9A 1891/4885NPC1 493/4885CYP3A4 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.